$PTCT
PTC Therapeutics Inc Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000107008122000041 Filed on October 27, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$167.4M	$217.1M	$138.7M
YoY Change	1.32%	56.5%	17.18%
Cost Of Revenue	$10.89M	$14.01M	$6.539M
YoY Change	16.79%	114.27%	39.13%
Gross Profit	$156.5M	$203.1M	$132.2M
YoY Change	0.4%	53.64%	16.27%
Gross Profit Margin	93.49%	93.55%	95.29%
Selling, General & Admin	$92.72M	$80.12M	$69.25M
YoY Change	7.13%	15.69%	19.73%
% of Gross Profit	59.24%	39.44%	52.38%
Research & Development	$188.7M	$165.5M	$130.8M
YoY Change	25.93%	26.46%	40.7%
% of Gross Profit	120.56%	81.46%	98.97%
Depreciation & Amortization	$38.87M	$34.48M	$16.75M
YoY Change	106.61%	105.83%	43.9%
% of Gross Profit	24.83%	16.97%	12.67%
Operating Expenses	$323.5M	$285.3M	$231.8M
YoY Change	34.43%	23.08%	33.59%
Operating Profit	-$167.0M	-$68.19M	-$93.08M
YoY Change	97.05%	-26.74%	68.83%
Interest Expense	-$39.70M	-$20.88M	-$21.80M
YoY Change	-4.11%	-4.23%	3.63%
% of Operating Profit
Other Income/Expense, Net	$50.35M	-$38.14M	-$18.78M
YoY Change	-503.56%	103.07%	-165.29%
Pretax Income	-$189.7M	-$127.2M	-$133.7M
YoY Change	36.86%	-4.83%	181.96%
Income Tax	-$18.80M	-$17.89M	-$36.00K
% Of Pretax Income
Net Earnings	-$170.9M	-$109.3M	-$133.6M
YoY Change	19.28%	-18.19%	91.74%
Net Earnings / Revenue	-102.08%	-50.35%	-96.31%
Basic Earnings Per Share		-$1.53	-$1.89
Diluted Earnings Per Share	-$2.35	-$1.53	-$1.893M
COMMON SHARES
Basic Shares Outstanding	71.88M	71.54M	70.60M
Diluted Shares Outstanding		71.65M	70.59M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$410.7M	$288.4M	$867.9M
YoY Change	-46.89%	-66.77%	-23.93%
Cash & Equivalents	$279.8M	$104.4M	$189.8M
Short-Term Investments	$130.9M	$184.0M	$678.1M
Other Short-Term Assets	$105.7M	$89.56M	$30.94M
YoY Change	93.23%	189.48%	15.01%
Inventory	$21.81M	$14.81M	$15.61M
Prepaid Expenses
Receivables	$155.6M	$124.5M	$96.65M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$693.8M	$517.3M	$1.011B
YoY Change	-27.3%	-48.84%	-18.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$72.59M	$66.89M	$46.35M
YoY Change	38.04%	44.3%	64.72%
Goodwill	$82.34M	$82.30M	$82.34M
YoY Change	0.0%	-0.05%	0.05%
Intangibles	$705.9M	$749.9M	$723.3M
YoY Change	-2.61%	3.68%	1.51%
Long-Term Investments
YoY Change
Other Assets	$48.58M	$55.12M	$65.53M
YoY Change	4.48%	-15.89%	133.21%
Total Long-Term Assets	$1.012B	$1.059B	$996.2M
YoY Change	2.86%	6.32%	6.33%
TOTAL ASSETS
Total Short-Term Assets	$693.8M	$517.3M	$1.011B
Total Long-Term Assets	$1.012B	$1.059B	$996.2M
Total Assets	$1.706B	$1.576B	$2.007B
YoY Change	-11.99%	-21.47%	-7.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$27.27M	$20.86M	$21.46M
YoY Change	18.39%	-2.8%	37.02%
Accrued Expenses	$126.1M	$99.12M	$82.05M
YoY Change	19.35%	20.81%	20.66%
Deferred Revenue	$1.351M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$75.15M	$80.55M	$149.4M
YoY Change	-49.75%	-46.07%
Total Short-Term Liabilities	$406.2M	$420.1M	$465.3M
YoY Change	-20.24%	-9.71%	83.3%
LONG-TERM LIABILITIES
Long-Term Debt	$571.7M	$282.7M	$281.6M
YoY Change	102.81%	0.41%	-7.05%
Other Long-Term Liabilities	$2.641M	$4.686M	$1.376M
YoY Change	-99.16%	240.55%	-30.08%
Total Long-Term Liabilities	$574.4M	$287.4M	$283.0M
YoY Change	103.75%	1.57%	-7.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$406.2M	$420.1M	$465.3M
Total Long-Term Liabilities	$574.4M	$287.4M	$283.0M
Total Liabilities	$2.053B	$1.803B	$1.902B
YoY Change	5.99%	-5.21%	13.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.657B	-$2.486B	-$1.955B
YoY Change	26.65%	27.19%	25.74%
Common Stock	$72.00K	$71.00K	$70.00K
YoY Change	1.41%	1.43%	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$347.1M	-$226.9M	$104.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.706B	$1.576B	$2.007B
YoY Change	-11.99%	-21.47%	-7.97%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$170.9M	-$109.3M	-$133.6M
YoY Change	19.28%	-18.19%	91.74%
Depreciation, Depletion And Amortization	$38.87M	$34.48M	$16.75M
YoY Change	106.61%	105.83%	43.9%
Cash From Operating Activities	-$166.0M	-$38.05M	-$51.19M
YoY Change	141.09%	-25.68%	-292.08%
INVESTING ACTIVITIES
Capital Expenditures	$8.622M	-$5.382M	-$5.844M
YoY Change	-198.81%	-7.91%	76.56%
Acquisitions
YoY Change
Other Investing Activities	$41.06M	$141.8M	$70.55M
YoY Change	-46.67%	101.04%	-118.05%
Cash From Investing Activities	$32.44M	$136.4M	$64.70M
YoY Change	-52.49%	110.88%	-116.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	302.9M	-140.0M	2.976M
YoY Change	6857.23%	-4804.13%	-99.54%
NET CHANGE
Cash From Operating Activities	-166.0M	-38.05M	-51.19M
Cash From Investing Activities	32.44M	136.4M	64.70M
Cash From Financing Activities	302.9M	-140.0M	2.976M
Net Change In Cash	169.4M	-41.60M	16.49M
YoY Change	4371.86%	-352.24%	-94.01%
FREE CASH FLOW
Cash From Operating Activities	-$166.0M	-$38.05M	-$51.19M
Capital Expenditures	$8.622M	-$5.382M	-$5.844M
Free Cash Flow	-$174.6M	-$32.66M	-$45.35M
YoY Change	190.42%	-27.97%	-251.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1350000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-81000
	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1792000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	222-7000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4052000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1316000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1377000
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	PTCT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	2054000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-109315000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-133624000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-388128000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-380636000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71654671
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70585938
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71415849
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70397846
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.53
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.89
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.41
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71854892
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70828226
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35969
	dei	Entity Registrant Name EntityRegistrantName	PTC Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3416587
	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Corporate Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Plainfield
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07080
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71882044
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104424000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189718000
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	184008000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	583658000
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	124456000
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	110455000
CY2022Q3	us-gaap	Inventory Net InventoryNet	14812000
CY2021Q4	us-gaap	Inventory Net InventoryNet	15856000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	89562000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	54681000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	517262000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	954368000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66889000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	749890000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	724841000
CY2022Q3	us-gaap	Goodwill Goodwill	82341000
CY2021Q4	us-gaap	Goodwill Goodwill	82341000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	104901000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77421000
CY2022Q3	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	55115000
CY2021Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	46500000
CY2022Q3	us-gaap	Assets Assets	1576398000
CY2021Q4	us-gaap	Assets Assets	1938056000
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	329322000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	288784000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	149540000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8895000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7273000
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2583000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000
CY2022Q3	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	77964000
CY2021Q4	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	59291000
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1312000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1460000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	420076000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	509348000
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	282749000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	281894000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	157700000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	239900000
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	137110000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	137110000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	102124000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73619000
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18675000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20053000
CY2022Q3	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	680182000
CY2021Q4	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	674694000
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4686000
CY2022Q3	us-gaap	Liabilities Liabilities	1803302000
CY2021Q4	us-gaap	Liabilities Liabilities	1936618000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71854892
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70828226
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	71000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	71000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2222905000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2123606000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	36205000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24282000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2486085000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2097957000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-226904000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1438000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1576398000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1938056000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	217127000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138743000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	531389000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	373364000
CY2022Q3	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	14011000
CY2021Q3	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	6539000
	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	33785000
	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	23001000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31023000
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14383000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80790000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38411000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	165462000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	130845000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	462802000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	390840000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	80118000
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	69252000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	233280000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	199225000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	5300000
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-10800000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	32200000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-11600000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	285314000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	231819000
	us-gaap	Operating Expenses OperatingExpenses	778457000
	us-gaap	Operating Expenses OperatingExpenses	663077000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-68187000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-93076000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-247068000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-289713000
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-20880000
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-21802000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-66371000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-63520000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38141000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18782000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-84355000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26499000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-127208000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-133660000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-397794000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-379732000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17893000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9666000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	904000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-109315000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-133624000
	us-gaap	Net Income Loss NetIncomeLoss	-388128000
	us-gaap	Net Income Loss NetIncomeLoss	-380636000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71654671
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70585938
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71415849
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70397846
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.89
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.41
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-109315000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-133624000
	us-gaap	Net Income Loss NetIncomeLoss	-388128000
	us-gaap	Net Income Loss NetIncomeLoss	-380636000
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	736000
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-136000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2333000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1505000
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	25218000
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-11319000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	13262000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	62820000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	29501000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83361000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120498000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-327641000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-352640000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-182218000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10005000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28670000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-109315000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	25954000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-226904000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	196577000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2976000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25871000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-133624000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	13126000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	104926000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1438000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13203000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3107000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82989000
	us-gaap	Net Income Loss NetIncomeLoss	-388128000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	60487000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-226904000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	481982000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16120000
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2627000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	77277000
	us-gaap	Net Income Loss NetIncomeLoss	-380636000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27996000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	104926000
	us-gaap	Net Income Loss NetIncomeLoss	-388128000
	us-gaap	Net Income Loss NetIncomeLoss	-380636000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89971000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45323000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7505000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5516000
	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	31617000
	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	14317000
	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	55778000
	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	57755000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-32200000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	11600000
	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	-1113000
	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	2376000
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-2392000
	us-gaap	Share Based Compensation ShareBasedCompensation	82989000
	us-gaap	Share Based Compensation ShareBasedCompensation	77277000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-71246000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-33280000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	768000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2476000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35615000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8161000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	24773000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	28625000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	3752000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	444000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1568000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8888000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-908000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4340000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4055000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-190691000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-182492000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23394000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19487000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	40429000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	276376000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22787000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	205382000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	341990000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	693319000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	104431000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	740000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	102069000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	41806000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	100000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	257742000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	150908000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13203000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16120000
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	150000000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3107000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2627000
	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	1276000
	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	2224000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-134966000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16523000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8792000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3933000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76707000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18994000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120511000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197318000
	us-gaap	Interest Paid Net InterestPaidNet	12679000
	us-gaap	Interest Paid Net InterestPaidNet	9589000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4029000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5527000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2333000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1505000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35294000
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	27828000
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	19154000
CY2022Q3	ptct	Milestone Payable MilestonePayable	50000000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Notes to Consolidated Financial Statements (unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">September 30, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">In thousands (except share and per share amounts unless otherwise noted)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have few or no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes that this allows it to maximize value for all of its stakeholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC has a portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Russia for the treatment of nmDMD in patients aged two years and older. In July 2020, the European Commission approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Translarna also has marketing authorization in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (“CNS”) including Upstaza (eladocagene exuparvovec) for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the European Commission approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. The Company is also preparing a biologics license application (“BLA”) for Upstaza for the treatment of AADC deficiency in the United States. In October 2022, the Company held a type C meeting with the FDA to discuss the details of a potential submission package for Upstaza. At such meeting, the FDA asked for additional bioanalytical data in support of comparability between the drug product used in the clinical studies and the commercial drug product. The Company is working with the FDA to address this request and it expects to submit a BLA to the FDA in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company holds the rights for the commercialization of Tegsedi® (inotersen) and Waylivra® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). The Company began to make commercial sales of Tegsedi for the treatment of hATTR amyloidosis in Brazil in the second quarter of 2022 and it continues to make Tegsedi available in certain other countries within Latin America and the Caribbean through early access programs (“EAP Programs”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil and the Company began to make commercial sales of Waylivra in Brazil in the third quarter of 2022 while continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP Programs. Waylivra has also received marketing authorization in the EU for the treatment of FCS. Additionally, the Company submitted an application to ANVISA in December 2021 for the approval of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Waylivra for the treatment of familial partial lipodystrophy, and it expects a regulatory decision on approval in the fourth quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the European Commission in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA and the Company expects the European Medicines Agency (“EMA”) to make a regulatory decision on approval for a label expansion for Evrysdi to include infants under two months old with SMA by the end of 2022. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company announced the results from its Phase 1 study of PTC518 in healthy volunteers in September 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid and protein levels, that PTC518 efficiently crosses the blood brain barrier at significant levels and that PTC518 was well tolerated. The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. Enrollment in the Phase 2 study remains active and ongoing outside of the United States. Enrollment within the United States is paused as the FDA has requested additional data to allow the Phase 2 study to proceed; discussions are ongoing with the FDA to allow the resumption of U.S. enrollment. The Company expects data from the initial 12-week phase of the Phase 2 study in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and utreloxastat, formerly known as PTC857. The Company initiated a registration-directed Phase 2/3 placebo-controlled trial of vatiquinone in children with mitochondrial disease associated seizures in the third quarter of 2020. The Company has completed enrollment in this trial after previously experiencing delays in enrollment due to the COVID-19 pandemic. The Company anticipates results from the Phase 2/3 trial to be available in the first quarter of 2023. The Company also initiated a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in the fourth quarter of 2020 and anticipates results from this trial to be available in the second quarter of 2023. In the third quarter of 2021, the Company completed a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of utreloxastat. Utreloxastat was found to be well-tolerated with no reported serious adverse events while demonstrating predictable pharmacology. The Company initiated a Phase 2 trial of utreloxastat for amyotrophic lateral sclerosis in the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The most advanced molecule in the Company’s metabolic platform is sepiapterin, formerly known as PTC923, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products, for orphan diseases. The Company initiated a registration-directed Phase 3 trial for <span style="background:#ffffff;">sepiapterin</span> for phenylketonuria (“PKU”) in the third quarter of 2021 and expects results from this trial to be available by the end of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has two oncology agents that are in clinical development, unesbulin and emvododstat. The Company completed its Phase 1 trials evaluating unesbulin in leiomyosarcoma (“LMS”) and diffuse intrinsic pontine glioma (“DIPG”) in the fourth quarter of 2021. The Company initiated a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the first quarter of 2022. The Company expects that initiation of a registration-directed Phase 2/3 trial of unesbulin for the treatment of DIPG will be delayed by at least one quarter. The Company completed its Phase 1 trial evaluating emvododstat in acute myeloid leukemia (“AML”), in the fourth quarter of 2021. The Company expects to provide further updates regarding its emvododstat program at a later date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2020, the Company initiated a Phase 2/3 clinical trial evaluating the efficacy and safety of emvododstat in patients hospitalized with COVID-19. In February 2021, the Company announced the completion of the first stage of the Phase </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2/3 trial. Given the changing nature of the COVID-19 pandemic to the outpatient treatment setting, the Company concluded enrollment in the Phase 2/3 trial early and has ended the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. The marketing authorization in the EEA was last renewed in June 2022 and is effective, unless extended, through August 5, 2023. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The Company refers to the trial and open-label extension together as Study 041. In June 2022, the Company announced top-line results from the placebo-controlled trial of Study 041. Within the placebo-controlled trial, Translarna showed a statistically significant treatment benefit across the entire intent to treat population as assessed by the 6-minute walk test, assessing ambulation and endurance, and in lower-limb muscle function as assessed by the North Star Ambulatory Assessment, a functional scale designed for boys affected by DMD. Additionally, Translarna showed a statistically significant treatment benefit across the intent to treat population within the 10-meter run/walk and 4-stair stair climb, each assessing ambulation and burst activity, while also showing a positive trend in the 4-stair stair descend although not statistically significant. Within the primary analysis group, Translarna demonstrated a positive trend across all endpoints, however, statistical significance was not achieved. Translarna was also well tolerated. In September 2022, as part of a specific obligation, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. The Company expects an opinion from the Committee for Medicinal Products for Human Use in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application (“NDA”) over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC’s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company followed the FDA’s recommendation and collected, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. Study 045 did not meet its pre-specified primary endpoint. In June 2022, the Company announced top-line results from the placebo-controlled trial of Study 041. The Company submitted a meeting request to the FDA to gain clarity on the regulatory pathway for a potential re-submission of an NDA for Translarna. While the FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness, the Company plans to pursue follow up discussions with the FDA to understand whether the evidence shown by entire intent to treat population in Study 041 along with confirmatory evidence from other studies could support approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2022, the Company had an accumulated deficit of approximately $2,486.1 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August 2015 of 3.00% convertible senior notes due 2022 (see Note 9), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offering" of its common stock, its initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), private placements of its convertible preferred stock, collaborations, bank and institutional lender debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. On August 15, 2022, the Company repaid the outstanding principal amount and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">accrued interest, totaling $152.3 million, of the 3.00% convertible senior notes due August 15, 2022 (the “2022 Convertible Notes”) that was due upon maturity in accordance with the terms of the notes. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months. </p>
	ptct	Number Of Products NumberOfProducts	2
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2486100000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104424000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189718000
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	16087000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	7500000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120511000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18700000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000.0
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20100000
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	6800000
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	5300000
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1231000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1418000
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	7070000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7721000
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6511000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6717000
CY2022Q3	us-gaap	Inventory Net InventoryNet	14812000
CY2021Q4	us-gaap	Inventory Net InventoryNet	15856000
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	300000
	us-gaap	Inventory Write Down InventoryWriteDown	1200000
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	500000
	us-gaap	Inventory Write Down InventoryWriteDown	2200000
CY2022Q3	ptct	Finance Lease Liability To Be Paid Year Four And After FinanceLeaseLiabilityToBePaidYearFourAndAfter	21000000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	271188000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	30000000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	160169000
CY2022Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	8742000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	111019000
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	21258000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2020Q3	ptct	Assigned Royalty Payment Retained Percentage AssignedRoyaltyPaymentRetainedPercentage	0.57067
CY2022Q3	ptct	Revenue Recognition Milestone Potential Achievements RevenueRecognitionMilestonePotentialAchievements	250000000.0
	ptct	Deferred Payroll Tax Liability Cares Act DeferredPayrollTaxLiabilityCaresAct	1300000
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
	ptct	State Tax Expense Benefit Irc Section174 Research And Development Expenses StateTaxExpenseBenefitIrcSection174ResearchAndDevelopmentExpenses	8700000
	ptct	Income Tax Benefit Valuation Allowance Release Ipr D Intangible Assets IncomeTaxBenefitValuationAllowanceReleaseIprDIntangibleAssets	18900000
CY2022Q3	ptct	Number Of Operating Leases NumberOfOperatingLeases	2
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2600000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	18000000.0
	us-gaap	Operating Lease Expense OperatingLeaseExpense	15900000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	5377000
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	4059000
	us-gaap	Operating Lease Cost OperatingLeaseCost	14267000
	us-gaap	Operating Lease Cost OperatingLeaseCost	12277000
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1151000
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1149000
	us-gaap	Variable Lease Cost VariableLeaseCost	3152000
	us-gaap	Variable Lease Cost VariableLeaseCost	3235000
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	262000
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	122000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	600000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	405000
CY2022Q3	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	6790000
CY2021Q3	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	5330000
	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	18019000
	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	15917000
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y10D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y10M13D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0864
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0891
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P10Y3M
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2021Q4	ptct	Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount	0
CY2022Q3	ptct	Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount	0
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	73934000
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2934000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	71000000
	us-gaap	Operating Lease Payments OperatingLeasePayments	10954000
	us-gaap	Operating Lease Payments OperatingLeasePayments	10254000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1276000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2224000
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1724000
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	776000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35294000
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2022Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1300000
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1600000
CY2021Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0.0
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	700000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3771000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15059000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3000000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18184000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20407000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3000000
CY2022Q3	ptct	Lessee Operating Lease Liability To Be Paid Year Four And After LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter	213767000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	377287000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	107000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	709000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	376685000
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2347000
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	55290000
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	587000
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	15710000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2934000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	71000000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	673000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	256801000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	36000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4985000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	709000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	261786000
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	36220000
CY2022Q3	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	34780000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	221611000
CY2021Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	155074000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.89
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.41
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	46371000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55733000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1287000
CY2022Q3	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	28326000
CY2021Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	26434000
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5076000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3547000
CY2022Q3	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	61401000
CY2021Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	61662000
CY2022Q3	ptct	Sales Rebates Current SalesRebatesCurrent	64937000
CY2021Q4	ptct	Sales Rebates Current SalesRebatesCurrent	68770000
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	41897000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	35679000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	20862000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23033000
CY2022Q3	ptct	Milestone Payable MilestonePayable	50000000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10452000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12639000
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	329322000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	288784000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-109315000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-133624000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-388128000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-380636000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71654671
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70585938
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71415849
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70397846
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13967365
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12418346
CY2022Q3	ptct	Numberofdistributors Numberofdistributors	2
CY2021Q3	ptct	Numberofdistributors Numberofdistributors	2
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28670000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25871000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	82989000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	77277000
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	200600000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M25D
CY2020Q3	ptct	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	650000000.0
CY2020Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.110
CY2021Q4	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	733985000
	ptct	Liability Sale Of Future Royalties Royalty Revenue Payable LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable	31617000
	ptct	Liability Sale Of Future Royalties Interest Expense LiabilitySaleOfFutureRoyaltiesInterestExpense	55778000
CY2022Q3	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	758146000
CY2022Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.094
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	ptct	Numberofdistributors Numberofdistributors	2
	ptct	Numberofdistributors Numberofdistributors	2
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
CY2022Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
CY2021Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000.0
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31000000.0
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14400000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80800000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38400000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	31411000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	125646000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	27613000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9093000
CY2022Q3	ptct	Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter	69176000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	262939000
	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0
CY2022Q3	us-gaap	Goodwill Goodwill	82300000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001070081-22-000041-index-headers.html	Edgar Link	pending
0001070081-22-000041-index.html	Edgar Link	pending
0001070081-22-000041.txt	Edgar Link	pending
0001070081-22-000041-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20221027.xsd	Edgar Link	pending
tmb-20221027x10q.htm	Edgar Link	pending
tmb-20221027xex10d1.htm	Edgar Link	pending
tmb-20221027xex10d2.htm	Edgar Link	pending
tmb-20221027xex10d2001.jpg	Edgar Link	pending
tmb-20221027xex31d1.htm	Edgar Link	pending
tmb-20221027xex31d2.htm	Edgar Link	pending
tmb-20221027xex32d1.htm	Edgar Link	pending
tmb-20221027xex32d2.htm	Edgar Link	pending
tmb-20221027_pre.xml	Edgar Link	unprocessable
tmb-20221027_cal.xml	Edgar Link	unprocessable
tmb-20221027_def.xml	Edgar Link	unprocessable
tmb-20221027_lab.xml	Edgar Link	unprocessable
tmb-20221027x10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC Therapeutics Inc Stock $ptct

2022 Q4 Form 10-Q Financial Statement

#000107008122000041 Filed on October 27, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC Therapeutics Inc Stock $ptct

2022 Q4 Form 10-Q Financial Statement

#000107008122000041 Filed on October 27, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC Therapeutics Inc Stock $ptct